

Franz X Vollenweider

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1942192/publications.pdf>

Version: 2024-02-01

126
papers

13,767
citations

17429

63
h-index

22808

112
g-index

137
all docs

137
docs citations

137
times ranked

7078
citing authors

#	ARTICLE	IF	CITATIONS
1	Classic Psychedelic Drugs: Update on Biological Mechanisms. <i>Pharmacopsychiatry</i> , 2022, 55, 121-138.	1.7	34
2	A neurobiological perspective on social influence: Serotonin and social adaptation. <i>Journal of Neurochemistry</i> , 2022, 162, 60-79.	2.1	11
3	Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice. <i>NeuroImage</i> , 2021, 225, 117456.	2.1	25
4	LSD and ketanserin and their impact on the human autonomic nervous system. <i>Psychophysiology</i> , 2021, 58, e13822.	1.2	19
5	Mapping brain-behavior space relationships along the psychosis spectrum. <i>ELife</i> , 2021, 10, .	2.8	21
6	Transcriptomics-informed large-scale cortical model captures topography of pharmacological neuroimaging effects of LSD. <i>ELife</i> , 2021, 10, .	2.8	22
7	Psilocybin Induces Aberrant Prediction Error Processing of Tactile Mismatch Responsesâ€”A Simultaneous EEGâ€”fMRI Study. <i>Cerebral Cortex</i> , 2021, 32, 186-196.	1.6	15
8	LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making. <i>Psychological Medicine</i> , 2020, 50, 2255-2264.	2.7	53
9	LSD-induced increases in social adaptation to opinions similar to oneâ€™s own are associated with stimulation of serotonin receptors. <i>Scientific Reports</i> , 2020, 10, 12181.	1.6	20
10	Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. <i>Nature Reviews Neuroscience</i> , 2020, 21, 611-624.	4.9	244
11	P300 â€”mediated modulations in selfâ€”other processing under psychedelic psilocybin are related to connectedness and changed meaning: A window into the selfâ€”other overlap. <i>Human Brain Mapping</i> , 2020, 41, 4982-4996.	1.9	22
12	Ketamine Affects Prediction Errors about Statistical Regularities: A Computational Single-Trial Analysis of the Mismatch Negativity. <i>Journal of Neuroscience</i> , 2020, 40, 5658-5668.	1.7	44
13	Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience. <i>Biomedicines</i> , 2020, 8, 34.	1.4	15
14	Psilocybin Induces Time-Dependent Changes in Global Functional Connectivity. <i>Biological Psychiatry</i> , 2020, 88, 197-207.	0.7	104
15	Effective connectivity changes in LSD-induced altered states of consciousness in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 2743-2748.	3.3	186
16	S159. NMDA Receptor Antagonism Effects on Delayed Spatial Working Memory and Distraction in Comparison With Schizophrenia. <i>Biological Psychiatry</i> , 2019, 85, S358.	0.7	0
17	S175. Large-Scale Model of Human Cortex Captures LSD-Induced Functional Alterations via HTR2A-Mediated Neural Gain Modulation. <i>Biological Psychiatry</i> , 2019, 85, S365.	0.7	0
18	Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. <i>NeuroImage</i> , 2019, 196, 207-215.	2.1	144

#	ARTICLE	IF	CITATIONS
19	Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. <i>European Neuropsychopharmacology</i> , 2019, 29, 539-548.	0.3	7
20	Modulation of Social Cognition via Hallucinogens and "Entactogens". <i>Frontiers in Psychiatry</i> , 2019, 10, 881.	1.3	29
21	Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. <i>Scientific Reports</i> , 2019, 9, 14914.	1.6	79
22	Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. <i>European Neuropsychopharmacology</i> , 2018, 28, 691-700.	0.3	48
23	Role of the 5-HT _{2A} Receptor in Self- and Other-Initiated Social Interaction in Lysergic Acid Diethylamide-Induced States: A Pharmacological fMRI Study. <i>Journal of Neuroscience</i> , 2018, 38, 3603-3611.	1.7	56
24	Serotonin 2A Receptor Signaling Underlies LSD-induced Alteration of the Neural Response to Dynamic Changes in Music. <i>Cerebral Cortex</i> , 2018, 28, 3939-3950.	1.6	34
25	Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT _{2A} receptor. <i>ELife</i> , 2018, 7, .	2.8	244
26	F157. HIERARCHICAL PREDICTION ERRORS DURING AUDITORY MISMATCH UNDER PHARMACOLOGICAL MANIPULATIONS: A COMPUTATIONAL SINGLE-TRIAL EEG ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S281-S282.	2.3	2
27	Neurobiologische Grundlagen der Wirkung von Psychedelika. , 2018, , 423-436.		0
28	The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation. <i>Current Biology</i> , 2017, 27, 451-457.	1.8	281
29	Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy male volunteers. <i>Psychopharmacology</i> , 2017, 234, 1957-1968.	1.5	17
30	Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. <i>Psychopharmacology</i> , 2017, 234, 2031-2046.	1.5	117
31	Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. <i>NeuroImage</i> , 2017, 159, 70-78.	2.1	61
32	Effect of Psilocybin on Empathy and Moral Decision-Making. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 747-757.	1.0	134
33	LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. <i>Frontiers in Pharmacology</i> , 2017, 8, 814.	1.6	70
34	Serotonergic Hallucinogen-Induced Visual Perceptual Alterations. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 257-282.	0.8	78
35	Phenomenology, Structure, and Dynamic of Psychedelic States. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 36, 221-256.	0.8	134
36	Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5119-5124.	3.3	125

#	ARTICLE	IF	CITATIONS
37	Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. <i>European Neuropsychopharmacology</i> , 2016, 26, 756-766.	0.3	97
38	The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. <i>NeuroImage: Clinical</i> , 2016, 11, 53-60.	1.4	75
39	Neurobiologische Grundlagen der Wirkung von Psychedelika. , 2016, , 1-18.		1
40	The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. <i>European Neuropsychopharmacology</i> , 2015, 25, 474-482.	0.3	11
41	Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. <i>Biological Psychiatry</i> , 2015, 78, 544-553.	0.7	340
42	Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. <i>Biological Psychiatry</i> , 2015, 78, 572-581.	0.7	206
43	The role of GABAB receptors in human reinforcement learning. <i>European Neuropsychopharmacology</i> , 2014, 24, 1606-1614.	0.3	4
44	Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy Low and High Gating Humans and Relation to Psychometry. <i>Neuropsychopharmacology</i> , 2014, 39, 2485-2496.	2.8	10
45	Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin. <i>Cerebral Cortex</i> , 2014, 24, 3221-3231.	1.6	47
46	The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. <i>Psychopharmacology</i> , 2013, 225, 227-239.	1.5	70
47	Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD). <i>Psychiatry Research</i> , 2013, 205, 117-126.	1.7	51
48	Increased Sensorimotor Gating in Recreational and Dependent Cocaine Users Is Modulated by Craving and Attention-Deficit/Hyperactivity Disorder Symptoms. <i>Biological Psychiatry</i> , 2013, 73, 225-234.	0.7	41
49	Activation of Serotonin 2A Receptors Underlies the Psilocybin-Induced Effects on α Oscillations, N170 Visual-Evoked Potentials, and Visual Hallucinations. <i>Journal of Neuroscience</i> , 2013, 33, 10544-10551.	1.7	240
50	Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch Negativity. <i>Cerebral Cortex</i> , 2013, 23, 2394-2406.	1.6	93
51	Mismatch Negativity Encoding of Prediction Errors Predicts S-ketamine-Induced Cognitive Impairments. <i>Neuropsychopharmacology</i> , 2012, 37, 865-875.	2.8	96
52	Psilocybin-Induced Deficits in Automatic and Controlled Inhibition are Attenuated by Ketanserin in Healthy Human Volunteers. <i>Neuropsychopharmacology</i> , 2012, 37, 630-640.	2.8	168
53	Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. <i>Biological Psychiatry</i> , 2012, 72, 898-906.	0.7	212
54	Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. <i>NeuroImage</i> , 2012, 59, 3922-3932.	2.1	30

#	ARTICLE	IF	CITATIONS
55	Prediction of Psilocybin Response in Healthy Volunteers. PLoS ONE, 2012, 7, e30800.	1.1	245
56	Crowding Deficits in the Visual Periphery of Schizophrenia Patients. PLoS ONE, 2012, 7, e45884.	1.1	14
57	Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology, 2011, 25, 1434-1452.	2.0	346
58	The 5-HT _{2A/1A} Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations. Biological Psychiatry, 2011, 69, 399-406.	0.7	54
59	The effects of sertindole on sensory gating, sensorimotor gating, and cognition in healthy volunteers. Journal of Psychopharmacology, 2011, 25, 1600-1613.	2.0	26
60	Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE, 2010, 5, e12412.	1.1	413
61	P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder. Journal of Affective Disorders, 2010, 126, 188-197.	2.0	54
62	The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 2010, 11, 642-651.	4.9	523
63	Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Na ⁺ -ve First-Episode Schizophrenia Patients. Neuropsychobiology, 2010, 61, 79-86.	0.9	31
64	Effects of a β -blocker on the cardiovascular response to MDMA (Ecstasy). Emergency Medicine Journal, 2010, 27, 586-589.	0.4	44
65	Potential antipsychotic properties of central cannabinoid (CB ₁) receptor antagonists. World Journal of Biological Psychiatry, 2010, 11, 208-219.	1.3	56
66	Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology, 2009, 23, 923-935.	2.0	40
67	Impaired Prepulse Inhibition and Prepulse-Elicited Reactivity but Intact Reflex Circuit Excitability in Unmedicated Schizophrenia Patients: a Comparison With Healthy Subjects and Medicated Schizophrenia Patients. Schizophrenia Bulletin, 2009, 35, 244-255.	2.3	42
68	GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Applied Radiation and Isotopes, 2009, 67, 598-601.	0.7	12
69	Sensorimotor Gating Depends on Polymorphisms of the Serotonin-2A Receptor and Catechol-O-Methyltransferase, but Not on Neuregulin-1 Arg38Gln Genotype: A Replication Study. Biological Psychiatry, 2009, 66, 614-620.	0.7	93
70	Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters, 2008, 435, 51-55.	1.0	57
71	Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences, 2008, 29, 445-453.	4.0	401
72	Sensorimotor gating and attentional set-shifting are improved by the μ -opioid receptor agonist morphine in healthy human volunteers. International Journal of Neuropsychopharmacology, 2008, 11, 655-69.	1.0	28

#	ARTICLE	IF	CITATIONS
73	Haloperidol Differentially Modulates Prepulse Inhibition and P50 Suppression in Healthy Humans Stratified for Low and High Gating Levels. <i>Neuropsychopharmacology</i> , 2008, 33, 497-512.	2.8	97
74	On the influence of baseline startle reactivity on the indexation of prepulse inhibition.. <i>Behavioral Neuroscience</i> , 2008, 122, 885-900.	0.6	104
75	Decision-Making Dysregulation in First-Episode Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2008, 196, 157-160.	0.5	5
76	The Effects of the Preferential 5-HT _{2A} Agonist Psilocybin on Prepulse Inhibition of Startle in Healthy Human Volunteers Depend on Interstimulus Interval. <i>Neuropsychopharmacology</i> , 2007, 32, 1876-1887.	2.8	142
77	Effects of psilocybin on time perception and temporal control of behaviour in humans. <i>Journal of Psychopharmacology</i> , 2007, 21, 50-64.	2.0	172
78	Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. <i>Psychopharmacology</i> , 2007, 195, 415-424.	1.5	103
79	Clozapine Enhances Prepulse Inhibition in Healthy Humans with Low But Not with High Prepulse Inhibition Levels. <i>Biological Psychiatry</i> , 2006, 60, 597-603.	0.7	60
80	The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. <i>Behavioural Brain Research</i> , 2006, 174, 143-150.	1.2	19
81	Modulating the Rate and Rhythmicity of Perceptual Rivalry Alternations with the Mixed 5-HT _{2A} and 5-HT _{1A} Agonist Psilocybin. <i>Neuropsychopharmacology</i> , 2005, 30, 1154-1162.	2.8	84
82	MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task. <i>Journal of Psychopharmacology</i> , 2005, 19, 366-374.	2.0	17
83	Using Psilocybin to Investigate the Relationship between Attention, Working Memory, and the Serotonin 1A and 2A Receptors. <i>Journal of Cognitive Neuroscience</i> , 2005, 17, 1497-1508.	1.1	183
84	The P3 in "ecstasy" polydrug users during response inhibition and execution. <i>Journal of Psychopharmacology</i> , 2005, 19, 504-512.	2.0	29
85	On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans. <i>Behavioural Brain Research</i> , 2005, 162, 256-263.	1.2	23
86	Rapid Visual Information Processing in Schizophrenic Patients: The Impact of Cognitive Load and Duration of Stimulus Presentation. <i>Neuropsychobiology</i> , 2005, 52, 130-134.	0.9	17
87	Information-processing deficits and cognitive dysfunction in panic disorder. <i>Journal of Psychiatry and Neuroscience</i> , 2005, 30, 37-43.	1.4	89
88	Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. <i>Psychopharmacology</i> , 2004, 172, 145-156.	1.5	321
89	Comparison of simultaneously recorded [H ₂ 15O]-PET and LORETA during cognitive and pharmacological activation. <i>Human Brain Mapping</i> , 2004, 22, 83-96.	1.9	48
90	Psilocybin impairs high-level but not low-level motion perception. <i>NeuroReport</i> , 2004, 15, 1947-1951.	0.6	51

#	ARTICLE	IF	CITATIONS
91	Decision-making strategies by panic disorder subjects are more sensitive to errors. <i>Journal of Affective Disorders</i> , 2003, 76, 183-189.	2.0	24
92	Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. <i>Biological Psychiatry</i> , 2003, 54, 121-128.	0.7	225
93	The acoustic startle reflex and its modulation: effects of age and gender in humans. <i>Biological Psychology</i> , 2003, 63, 311-323.	1.1	92
94	Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. <i>Psychiatry Research</i> , 2003, 119, 293-306.	1.7	23
95	Effects of the 5-HT _{2A} Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia. <i>Neuropsychopharmacology</i> , 2003, 28, 170-181.	2.8	154
96	Acute Psychological and Neurophysiological Effects of MDMA in Humans. <i>Journal of Psychoactive Drugs</i> , 2002, 34, 171-184.	1.0	71
97	Mismatch negativity predicts psychotic experiences induced by nmda receptor antagonist in healthy volunteers. <i>Biological Psychiatry</i> , 2002, 51, 400-406.	0.7	217
98	Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. <i>Biological Psychiatry</i> , 2002, 52, 729-739.	0.7	121
99	Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. <i>Schizophrenia Research</i> , 2002, 55, 129-137.	1.1	103
100	PET imaging of dopamine transporters in the human brain using [¹¹ C]-β ² -CPPIT, a cocaine derivative lacking the 2 nd -ester function. <i>Nuclear Medicine and Biology</i> , 2002, 29, 19-27.	0.3	13
101	The relationship between co-recorded [H ₂ 15O]-PET and EEG functional tomography (LORETA) before and during pharmacological activation. <i>International Congress Series</i> , 2002, 1232, 247-251.	0.2	1
102	Prepulse inhibition deficits in patients with panic disorder. <i>Depression and Anxiety</i> , 2002, 15, 55-60.	2.0	143
103	Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2002, 30, 331-339.	1.4	71
104	A neural network approach to the acoustic startle reflex and prepulse inhibition. <i>Brain Research Bulletin</i> , 2001, 56, 101-110.	1.4	19
105	A systems model of altered consciousness: integrating natural and drug-induced psychoses. <i>Brain Research Bulletin</i> , 2001, 56, 495-507.	1.4	267
106	No Difference in Brain Activation During Cognitive Performance Between Ecstasy (3,4-Methylenedioxyamphetamine) Users and Control Subjects: A [H ₂ 15O]-Positron Emission Tomography Study. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 66-71.	0.7	58
107	Gender differences in the subjective effects of MDMA. <i>Psychopharmacology</i> , 2001, 154, 161-168.	1.5	283
108	Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. <i>Human Psychopharmacology</i> , 2001, 16, 589-598.	0.7	195

#	ARTICLE	IF	CITATIONS
109	Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA). <i>Human Brain Mapping</i> , 2001, 14, 152-165.	1.9	157
110	Effects of MDMA (Ecstasy) on Prepulse Inhibition and Habituation of Startle in Humans after Pretreatment with Citalopram, Haloperidol, or Ketanserin. <i>Neuropsychopharmacology</i> , 2001, 24, 240-252.	2.8	93
111	Caveat Emptor Editors Beware. <i>Neuropsychopharmacology</i> , 2001, 24, 461-463.	2.8	27
112	Brain mechanisms of hallucinogens and entactogens. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 265-279.	1.8	97
113	Mood state and brain electric activity in Ecstasy users. <i>NeuroReport</i> , 2000, 11, 157-162.	0.6	73
114	Psychological and Physiological Effects of MDMA (Ecstasy) after Pretreatment with the 5-HT2 Antagonist Ketanserin in Healthy Humans. <i>Neuropsychopharmacology</i> , 2000, 23, 396-404.	2.8	203
115	3,4-Methylenedioxymethamphetamine (MDMA) Modulates Cortical and Limbic Brain Activity as Measured by [H215O]-PET in Healthy Humans. <i>Neuropsychopharmacology</i> , 2000, 23, 388-395.	2.8	116
116	Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) are Attenuated by the Serotonin Uptake Inhibitor Citalopram. <i>Neuropsychopharmacology</i> , 2000, 22, 513-521.	2.8	215
117	Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans. <i>Journal of Psychiatric Research</i> , 2000, 34, 35-43.	1.5	207
118	Ketamine-Induced Deficits in Auditory and Visual Context-Dependent Processing in Healthy Volunteers. <i>Archives of General Psychiatry</i> , 2000, 57, 1139.	13.8	552
119	The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (Ecstasy™) in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2000, 14, 269-274.	2.0	127
120	Acute psychological and physiological effects of MDMA (Ecstasy) after haloperidol pretreatment in healthy humans. <i>European Neuropsychopharmacology</i> , 2000, 10, 289-295.	0.3	124
121	5-HT Modulation of Dopamine Release in Basal Ganglia in Psilocybin-Induced Psychosis in Man: A PET Study with [11C]raclopride. <i>Neuropsychopharmacology</i> , 1999, 20, 424-433.	2.8	233
122	Correspondence. <i>Neuropsychopharmacology</i> , 1999, 21, 598-600.	2.8	39
123	Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 149-162.	0.9	68
124	Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. <i>NeuroReport</i> , 1998, 9, 3897-3902.	0.6	779
125	Psychological and Cardiovascular Effects and Short-Term Sequelae of MDMA (Ecstasy) in MDMA-Naïve Healthy Volunteers. <i>Neuropsychopharmacology</i> , 1998, 19, 241-251.	2.8	200
126	Effect of Climbing Fibre Deprivation on the K+-evoked Release of Endogenous Adenosine from Rat Cerebellar Slices. <i>European Journal of Neuroscience</i> , 1991, 3, 201-208.	1.2	12